Gynecological Cancer GOG 3012

Sponsor: Gynecologic Oncology Group/Tesaro

Number: GOG 3012

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Niraparib works by inhibiting PARP, a protein that helps cancer cells repair DNA that has been damaged by cancer treatments, especially in cancers with mutated BRCA. When cancer cells repair damaged DNA, they can continue growing and multiplying, so depriving them of this power with a PARP inhibitor may be an effective approach to treatment.

Patients in this study will be randomly assigned to receive niraparib or a placebo. Niraparib is taken orally (by mouth).

Who’s eligible:

  • Patients must have stage III or IV ovarian cancer that shrank following initial chemotherapy that included platinum-containing drugs.
  • Patients must join the study within 12 weeks of the first day of their last cycle of chemotherapy.

 Available at: The Hospital of Central Connecticut and Hartford Hospital.

Cancer Clinical Research Office